Pharmaceutical Business Review

APRIL 17, 2024

This partnership is set to enhance the treatment options available to diabetes patients in Brazil. It develops, manufactures and commercialises complex biotech and biosimilar drug products at its production facility in Nova Lima. million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF).

Diabetes 59

Diabetes Biosimilars 59

Express Pharma

AUGUST 8, 2024

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.

Biosimilars 102

Biosimilars Diabetes 102

FDA Law Blog: Biosimilars

JULY 10, 2024

Another patient shared their journey with diabetes. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030. This patient had used wearable devices on their own in the past but did not understand how to use the data to manage their health.

Diabetes 59

Diabetes 59

PharmaShots

APRIL 3, 2023

old, for use by women with diabetes who are pregnant & for wear time of up to 15 days. of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The results also showed a reduction in risk of hospitalization for any cause with 14% relative risk reduction (24.8

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

Express Pharma

JANUARY 3, 2025

While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.

Biosimilars 105

Biosimilars Vaccines Diabetes 105